On May 28, 2025 Archeus Technologies, a company developing multiple differentiated radiopharmaceutical therapies, and the Wisconsin Alumni Research Foundation (WARF), the patenting and licensing arm of the University of Wisconsin–Madison (UW), reported a strategic collaboration to advance ART-101 – a promising receptor-based targeting molecule – into clinical development (Press release, Archeus Technologies, MAY 28, 2025, View Source [SID1234653474]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ART-101 was discovered and developed at the Advanced Radiotheranostics Lab at UW–Madison, led by Dr. Reinier Hernandez, assistant professor of medical physics at the University of Wisconsin School of Medicine and Public Health. Aided by robust support from WARF through the WARF Accelerator, ART-101 has demonstrated enhanced pharmacology in preclinical studies, including significantly higher tumor uptake and retention relative to FDA-approved prostate cancer treatment Pluvicto (177Lu-PSMA-617). It has also shown superior pharmacokinetics, dosimetry and normal tissue toxicity profiles.
Through a collaboration agreement with WARF, Archeus Technologies will lead Phase 1 clinical development of this asset with trial initiation planned for 2025. ART-101 is a next-generation prostate-specific membrane antigen (PSMA)-targeting small molecule. It is being evaluated as a radiopharmaceutical agent with the potential to deliver alpha-emitting isotopes with greater tolerability compared with current standards of care.
"With strong preclinical data supporting the continued development of ART-101, Archeus is eager to lead the evaluation of this novel candidate through first-in-human studies," said Evan Sengbusch, Ph.D., chief executive officer of Archeus Technologies. "Leveraging our team’s proven experience ushering new radiopharmaceutical agents from concept through clinical translation, paired with our close collaboration with UW as a world-class radiopharmaceutical research organization, Archeus is uniquely positioned to progress ART-101 into the next stage of development. This asset adds to our Phase 1-ready portfolio of differentiated radiopharmaceutical therapies with the potential to provide curative responses to cancers that are particularly challenging to treat."
"WARF is committed to investing in cutting-edge technologies and therapeutic candidates, like ART-101, that have significant potential to advance the theranostics landscape as well as treatment options for patients in need," said Jeanine Burmania, senior director of intellectual property and licensing at WARF. "Encouraging preclinical data suggest that ART-101 could help increase lifespan and be more effective in treating prostate cancer than current therapies. We’re pleased to partner with Archeus Technologies to continue the development of this innovative asset and look forward to better understanding its role to potentially improve outcomes for prostate cancer patients."
ART-101 is compatible with multiple therapeutic isotopes, including actinium-225, lutetium-177 and terbium-161. When paired with these isotopes, preclinical data show that ART-101 provides significant potential benefit that could lead to improved outcomes for prostate cancer patients.